Fibroblast growth factor 23, klotho and heparin.
Journal
Current opinion in nephrology and hypertension
ISSN: 1473-6543
Titre abrégé: Curr Opin Nephrol Hypertens
Pays: England
ID NLM: 9303753
Informations de publication
Date de publication:
01 07 2023
01 07 2023
Historique:
medline:
30
6
2023
pubmed:
17
5
2023
entrez:
17
5
2023
Statut:
ppublish
Résumé
Fibroblast growth factor (FGF) 23 is a bone-derived hormone that regulates phosphate and vitamin D metabolism by targeting the kidney. When highly elevated, such as in chronic kidney disease (CKD), FGF23 can also target the heart and induce pathologic remodeling. Here we discuss the mechanisms that underlie the physiologic and pathologic actions of FGF23, with focus on its FGF receptors (FGFR) and co-receptors. Klotho is a transmembrane protein that acts as an FGFR co-receptor for FGF23 on physiologic target cells. Klotho also exists as a circulating variant, and recent studies suggested that soluble klotho (sKL) can mediate FGF23 effects in cells that do not express klotho. Furthermore, it has been assumed that the actions of FGF23 do not require heparan sulfate (HS), a proteoglycan that acts as a co-receptor for other FGF isoforms. However, recent studies revealed that HS can be part of the FGF23:FGFR signaling complex and modulate FGF23-induced effects. sKL and HS have appeared as circulating FGFR co-receptors that modulate the actions of FGF23. Experimental studies suggest that sKL protects from and HS accelerates CKD-associated heart injury. However, the in vivo relevance of these findings is still speculative.
Identifiants
pubmed: 37195242
doi: 10.1097/MNH.0000000000000895
pii: 00041552-202307000-00003
pmc: PMC10241433
doi:
Substances chimiques
Fibroblast Growth Factor-23
7Q7P4S7RRE
Fibroblast Growth Factors
62031-54-3
Glucuronidase
EC 3.2.1.31
Heparin
9005-49-6
Receptors, Fibroblast Growth Factor
0
Types de publication
Review
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
313-323Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK125459
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL145528
Pays : United States
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004; 20:563–569.
Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16:139–149.
Ornitz DM. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 2000; 22:108–112.
Faham S, Linhardt RJ, Rees DC. Diversity does make a difference: fibroblast growth factor-heparin interactions. Curr Opin Struct Biol 1998; 8:578–586.
Goetz R, Ohnishi M, Kir S, et al. Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J Biol Chem 2012; 287:29134–29146.
Asada M, Shinomiya M, Suzuki M, et al. Glycosaminoglycan affinity of the complete fibroblast growth factor family. Biochim Biophys Acta 2009; 1790:40–48.
Goetz R, Beenken A, Ibrahimi OA, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 27:3417–3428.
Harmer NJ, Pellegrini L, Chirgadze D, et al. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 2004; 43:629–640.
Kharitonenkov A. FGFs and metabolism. Curr Opin Pharmacol 2009; 9:805–810.
Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 2013; 75:503–533.
Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19:429–435.
Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117:4003–4008.
Saito H, Maeda A, Ohtomo S, et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005; 280:2543–2549.
Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004; 314:409–414.
Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008; 118:3820–3828.
Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79:1370–1378.
Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305:2432–2439.
Isakova T, Cai X, Lee J, et al. Longitudinal FGF23 trajectories and mortality in patients with CKD. J Am Soc Nephrol 2018; 29:579–590.
Richter B, Faul C. FGF23 actions on target tissues-with and without klotho. Front Endocrinol (Lausanne) 2018; 9:189.
Quarles LD. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res 2012; 318:1040–1048.
Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121:4393–4408.
Grabner A, Amaral AP, Schramm K, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 2015; 22:1020–1032.
Grabner A, Schramm K, Silswal N, et al. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. Sci Rep 2017; 7:1993.
Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119:2545–2552.
Han X, Cai C, Xiao Z, Quarles LD. FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice. J Mol Cell Cardiol 2019; 138:66–74.
Touchberry CD, Green TM, Tchikrizov V, et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab 2013; 304:E863–E873.
Navarro-Garcia JA, Delgado C, Fernandez-Velasco M, et al. Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes. Nephrol Dial Transplant 2019; 34:1864–1875.
Chen G, Liu Y, Goetz R, et al. alpha-Klotho is a nonenzymatic molecular scaffold for FGF23 hormone signalling. Nature 2018; 553:461–466.
Yanucil C, Kentrup D, Campos I, et al. Soluble alpha-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2022; 102:261–279.
Imura A, Iwano A, Tohyama O, et al. Secreted Klotho protein in sera and CSF: implication for posttranslational cleavage in release of Klotho protein from cell membrane. FEBS Lett 2004; 565 (1–3):143–147.
Xu Y, Sun Z. Regulation of S-formylglutathione hydrolase by the antiaging gene klotho. Oncotarget 2017; 8:88259–88275.
Zhong X, Jagarlapudi S, Weng Y, et al. Structure-function relationships of the soluble form of the antiaging protein Klotho have therapeutic implications for managing kidney disease. J Biol Chem 2020; 295:3115–3133.
Chen CD, Podvin S, Gillespie E, et al. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci USA 2007; 104:19796–19801.
Chen CD, Tung TY, Liang J, et al. Identification of cleavage sites leading to the shed form of the antiaging protein klotho. Biochemistry 2014; 53:5579–5587.
Lindberg K, Amin R, Moe OW, et al. The kidney is the principal organ mediating klotho effects. J Am Soc Nephrol 2014; 25:2169–2175.
Hu MC, Shi M, Zhang J, et al. Renal production, uptake, and handling of circulating alphaklotho. J Am Soc Nephrol 2016; 27:79–90.
Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281:6120–6123.
Smith RC, O’Bryan LM, Farrow EG, et al. Circulating alphaKlotho influences phosphate handling by controlling FGF23 production. J Clin Invest 2012; 122:4710–4715.
Hum JM, O’Bryan LM, Tatiparthi AK, et al. Chronic hyperphosphatemia and vascular calcification are reduced by stable delivery of soluble klotho. J Am Soc Nephrol 2016; 28:1162–1174.
Kawai M, Kinoshita S, Kimoto A, et al. FGF23 suppresses chondrocyte proliferation in the presence of soluble alpha-Klotho both in vitro and in vivo. J Biol Chem 2013; 288:2414–2427.
Xiao Z, King G, Mancarella S, et al. FGF23 expression is stimulated in transgenic alpha-Klotho longevity mouse model. JCI Insight 2019; 4:e132820.
Shalhoub V, Ward SC, Sun B, et al. Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif Tissue Int 2011; 89:140–150.
Goetz R, Nakada Y, Hu MC, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci USA 2010; 107:407–412.
Goetz R, Ohnishi M, Ding X, et al. Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. Mol Cell Biol 2012; 32:1944–1954.
Suzuki Y, Kuzina E, An SJ, et al. FGF23 contains two distinct high-affinity binding sites enabling bivalent interactions with alpha-Klotho. Proc Natl Acad Sci USA 2020; 117:31800–31807.
Agrawal A, Ni P, Agoro R, et al. Identification of a second Klotho interaction site in the C terminus of FGF23. Cell Rep 2021; 34:108665.
Yu X, Ibrahimi OA, Goetz R, et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 2005; 146:4647–4656.
Zhang X, Ibrahimi OA, Olsen SK, et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006; 281:15694–15700.
Singh S, Grabner A, Yanucil C, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int 2016; 90:985–996.
Gattineni J, Alphonse P, Zhang Q, et al. Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4. Am J Physiol Renal Physiol 2014; 306:F351–F358.
Gattineni J, Bates C, Twombley K, et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 2009; 297:F282–F291.
Liu S, Vierthaler L, Tang W, et al. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 2008; 19:2342–2350.
Roig-Soriano J, Sanchez-de-Diego C, Esandi-Jauregui J, et al. Differential toxicity profile of secreted and processed alpha-Klotho expression over mineral metabolism and bone microstructure. Sci Rep 2023; 13:4211.
Hu MC, Shi M, Zhang J, et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010; 24:3438–3450.
Chen TH, Kuro OM, Chen CH, et al. The secreted Klotho protein restores phosphate retention and suppresses accelerated aging in Klotho mutant mice. Eur J Pharmacol 2013; 698 (1–3):67–73.
Hu MC, Shi M, Gillings N, et al. Recombinant alpha-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy. Kidney Int 2017; 91:1104–1114.
Andrukhova O, Bayer J, Schuler C, et al. Klotho lacks an FGF23-independent role in mineral homeostasis. J Bone Miner Res 2017; 32:2049–2061.
Erben RG. alpha-Klotho's effects on mineral homeostasis are fibroblast growth factor-23 dependent. Curr Opin Nephrol Hypertens 2018; 27:229–235.
Brownstein CA, Adler F, Nelson-Williams C, et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci USA 2008; 105:3455–3460.
Hum JM, O’Bryan L, Smith RC, White KE. Novel functions of circulating Klotho. Bone 2017; 100:36–40.
Carrillo-Lopez N, Panizo S, Alonso-Montes C, et al. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease. Kidney Int 2016; 90:77–89.
Kinoshita Y, Takashi Y, Ito N, et al. Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO). Bone Rep 2019; 10:100192.
Hu MC, Shi M, Cho HJ, et al. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol 2015; 26:1290–1302.
Xie J, Yoon J, An SW, et al. Soluble klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate. J Am Soc Nephrol 2015; 26:1150–1160.
Yang K, Wang C, Nie L, et al. Klotho protects against indoxyl sulphate-induced myocardial hypertrophy. J Am Soc Nephrol 2015; 26:2434–2446.
Grabner A, Faul C. The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy. Curr Opin Nephrol Hypertens 2016; 25:314–324.
Goetz R, Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol 2013; 14:166–180.
Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444:770–774.
Guan X, Nie L, He T, et al. Klotho suppresses renal tubulo-interstitial fibrosis by controlling basic fibroblast growth factor-2 signalling. J Pathol 2014; 234:560–572.
Mencke R, Olauson H, Hillebrands JL. Effects of Klotho on fibrosis and cancer: a renal focus on mechanisms and therapeutic strategies. Adv Drug Deliv Rev 2017; 121:85–100.
Fon Tacer K, Bookout AL, Ding X, et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 2010; 24:2050–2064.
Chang Q, Hoefs S, van der Kemp AW, et al. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 2005; 310:490–493.
Cha SK, Ortega B, Kurosu H, et al. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci USA 2008; 105:9805–9810.
Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. Science 2005; 309:1829–1833.
Kuro OM. The Klotho proteins in health and disease. Nat Rev Nephrol 2019; 15:27–44.
Dalton G, An SW, Al-Juboori SI, et al. Soluble klotho binds monosialoganglioside to regulate membrane microdomains and growth factor signaling. Proc Natl Acad Sci USA 2017; 114:752–757.
Wright JD, An SW, Xie J, et al. Modeled structural basis for the recognition of alpha2-3-sialyllactose by soluble Klotho. FASEB J 2017; 31:3574–3586.
Dalton GD, Xie J, An SW, Huang CL. New insights into the mechanism of action of soluble klotho. Front Endocrinol (Lausanne) 2017; 8:323.
Wright JD, An SW, Xie J, et al. Soluble klotho regulates TRPC6 calcium signaling via lipid rafts, independent of the FGFR-FGF23 pathway. FASEB J 2019; 33:9182–9193.
Zhou L, Mo H, Miao J, et al. Klotho ameliorates kidney injury and fibrosis and normalizes blood pressure by targeting the renin-angiotensin system. Am J Pathol 2015; 185:3211–3223.
Doi S, Zou Y, Togao O, et al. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 2011; 286:8655–8665.
Yuan Q, Ren Q, Li L, et al. A Klotho-derived peptide protects against kidney fibrosis by targeting TGF-beta signaling. Nat Commun 2022; 13:438.
Isakova T, Yanucil C, Faul C. A klotho-derived peptide as a possible novel drug to prevent kidney fibrosis. Am J Kidney Dis 2022; 80:285–288.
Chen X, Tan H, Xu J, et al. Klotho-derived peptide 6 ameliorates diabetic kidney disease by targeting Wnt/beta-catenin signaling. Kidney Int 2022; 102:506–520.
Speer T, Schunk SJ. Klotho in diabetic kidney disease: more than dust in the Wnt. Kidney Int 2022; 102:469–471.
Schlessinger J, Plotnikov AN, Ibrahimi OA, et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 2000; 6:743–750.
Ibrahimi OA, Yeh BK, Eliseenkova AV, et al. Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization. Mol Cell Biol 2005; 25:671–684.
Spivak-Kroizman T, Lemmon MA, Dikic I, et al. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 1994; 79:1015–1024.
Yayon A, Klagsbrun M, Esko JD, et al. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64:841–848.
Kan M, Wu X, Wang F, McKeehan WL. Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem 1999; 274:15947–15952.
Loo BM, Kreuger J, Jalkanen M, et al. Binding of heparin/heparan sulfate to fibroblast growth factor receptor 4. J Biol Chem 2001; 276:16868–16876.
Powell AK, Fernig DG, Turnbull JE. Fibroblast growth factor receptors 1 and 2 interact differently with heparin/heparan sulfate. Implications for dynamic assembly of a ternary signaling complex. J Biol Chem 2002; 277:28554–28563.
Baum M, Schiavi S, Dwarakanath V, Quigley R. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int 2005; 68:1148–1153.
Yamashita T, Konishi M, Miyake A, et al. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 2002; 277:28265–28270.
Zang L, Zhu H, Wang K, et al. Not just anticoagulation-new and old applications of heparin. Molecules 2022; 27:6968.
Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010; 21:1427–1435.
Zhang J, Liang L, Yang W, et al. Expedient synthesis of a library of heparan sulfate-like “head-to-tail” linked multimers for structure and activity relationship studies. Angew Chem Int Ed Engl 2022; 61:e202209730.
Xu R, Ori A, Rudd TR, et al. Diversification of the structural determinants of fibroblast growth factor-heparin interactions: implications for binding specificity. J Biol Chem 2012; 287:40061–40073.
Li Y, Sun C, Yates EA, et al. Heparin binding preference and structures in the fibroblast growth factor family parallel their evolutionary diversification. Open Biol 2016; 6:
Makarenkova HP, Hoffman MP, Beenken A, et al. Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis. Sci Signal 2009; 2:ra55.
Aviezer D, Safran M, Yayon A. Heparin differentially regulates the interaction of fibroblast growth factor-4 with FGF receptors 1 and 2. Biochem Biophys Res Commun 1999; 263:621–626.
Guimond S, Maccarana M, Olwin BB, et al. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem 1993; 268:23906–23914.
Allen BL, Filla MS, Rapraeger AC. Role of heparan sulfate as a tissue-specific regulator of FGF-4 and FGF receptor recognition. J Cell Biol 2001; 155:845–858.